Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

blinatumomab 4fludarabine 3Rituximab 3Cyclophosphamide 3ponatinib 2ibrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bone Marrow Transplantation 2venetoclax 1tetulomab tetraxetan lu-177 1pomalidomide 1obinutuzumab 1durvalumab 1dacetuzumab 1amonafide 1acalabrutinib 1Tinzaparin 1Lutetium-177 1Lutetium 1Lenalidomide 1Imatinib Mesylate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × amonafide × Other hematologic neoplasm × Clear all
NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡